Stephan Braun

Summary

Affiliation: Innsbruck Medical University
Country: Austria

Publications

  1. ncbi Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy
    Stephan Braun
    Department of Ob Gyn, University Hospital, Innsbruck, Austria
    Breast 12:397-404. 2003
  2. ncbi A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
  3. ncbi Circulating and disseminated tumor cells
    Stephan Braun
    Innsbruck Medical University, Department of Obstetrics and Gynecology, Breast Health Center, Anichstrasse 35 A 6020 Innsbruck Austria
    J Clin Oncol 23:1623-6. 2005
  4. ncbi Disseminated tumor cells: are they ready for clinical use?
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    Breast 16:S51-4. 2007
  5. ncbi The prognostic impact of bone marrow micrometastases in women with breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    Cancer Invest 27:598-603. 2009
  6. pmc Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstrasse 35, AT 6020 Innsbruck, Austria
    J Med Case Reports 5:316. 2011
  7. doi Immunocytochemical detection and characterisation of individual micrometastatic tumour cells
    Stephan Braun
    Universitätsklinik für Gynäkologie und Geburtshilfe Medizinische Universität Innsbruck, Innsbruck, Austria
    Methods Mol Biol 878:63-70. 2012
  8. ncbi Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer
    Alain G Zeimet
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    Anticancer Res 29:2803-8. 2009
  9. ncbi The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence
    Wolfgang Janni
    I Frauenklinik, Klinikum der Ludwig Maximilians Universtitaet, Muenchen, Germany
    Cancer 103:884-91. 2005
  10. ncbi Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy
    Holger Thurm
    Institute for Tumor Biology, University Hospital Hamburg Eppendorf, D 20246 Hamburg, Germany
    Clin Cancer Res 9:2598-604. 2003

Collaborators

Detail Information

Publications17

  1. ncbi Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy
    Stephan Braun
    Department of Ob Gyn, University Hospital, Innsbruck, Austria
    Breast 12:397-404. 2003
    ..Except for promising pilot studies, no data are available to support the immediate use of bone marrow evaluation for treatment monitoring in order to enable the prediction of response to adjuvant therapy...
  2. ncbi A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
    ..We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis...
  3. ncbi Circulating and disseminated tumor cells
    Stephan Braun
    Innsbruck Medical University, Department of Obstetrics and Gynecology, Breast Health Center, Anichstrasse 35 A 6020 Innsbruck Austria
    J Clin Oncol 23:1623-6. 2005
  4. ncbi Disseminated tumor cells: are they ready for clinical use?
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    Breast 16:S51-4. 2007
    ..Consequently, this important question is to be addressed in well-designed clinical trials...
  5. ncbi The prognostic impact of bone marrow micrometastases in women with breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    Cancer Invest 27:598-603. 2009
    ....
  6. pmc Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstrasse 35, AT 6020 Innsbruck, Austria
    J Med Case Reports 5:316. 2011
    ..abstract:..
  7. doi Immunocytochemical detection and characterisation of individual micrometastatic tumour cells
    Stephan Braun
    Universitätsklinik für Gynäkologie und Geburtshilfe Medizinische Universität Innsbruck, Innsbruck, Austria
    Methods Mol Biol 878:63-70. 2012
    ....
  8. ncbi Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer
    Alain G Zeimet
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    Anticancer Res 29:2803-8. 2009
    ....
  9. ncbi The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence
    Wolfgang Janni
    I Frauenklinik, Klinikum der Ludwig Maximilians Universtitaet, Muenchen, Germany
    Cancer 103:884-91. 2005
    ..If the persistence of ITCs after adjuvant therapy confers a similar risk for recurrence, then it would be an indication to consider secondary adjuvant therapy...
  10. ncbi Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy
    Holger Thurm
    Institute for Tumor Biology, University Hospital Hamburg Eppendorf, D 20246 Hamburg, Germany
    Clin Cancer Res 9:2598-604. 2003
    ..The subsequent 27 BM aspirates were specifically enriched for Ep-CAM(+) cells using magnetic beads coupled to Mab 3B10, and tumor cells were identified by Fab fragments of Mab A45-B/B3 directly conjugated with alkaline phosphatase...
  11. ncbi Detection and clinical implications of early systemic tumor cell dissemination in breast cancer
    Klaus Pantel
    Institut für Tumorbiologie, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 9:6326-34. 2003
    ..Here, we will review the existing tumor cell assays and discuss their current clinical relevance and perspectives for the clinical management of breast cancer patients...
  12. ncbi Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus
    Wolfgang Janni
    Department of Gynecology and Obstetrics, I Frauenklinik, Klinikum der Ludwig Maximilians Universtitaet, Muenchen, Germany
    Cancer 97:405-11. 2003
    ..This study evaluates the prevalence and prognostic significance of ITC in patients with primary carcinoma of the cervix uteri...
  13. ncbi A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tubingen, Tubingen, Germany
    Cancer 107:885-92. 2006
    ....
  14. ncbi Immunomagnetic CD45 depletion does not improve cytokeratin 20 RT-PCR in colorectal cancer
    Christoph Ausch
    Department of Surgery, Ludwig Boltzmann Research Institute of Surgical Oncology, Danube Hospital SMZ Ost, Vienna, Austria
    Clin Chem Lab Med 45:351-6. 2007
    ....
  15. ncbi Detection and measurement of occult disease for the prognosis of solid tumors
    Tracy G Lugo
    Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD 20892, USA
    J Clin Oncol 21:2609-15. 2003
  16. ncbi Circulating tumor cells in metastatic breast cancer--toward individualized treatment?
    Stephan Braun
    N Engl J Med 351:824-6. 2004
  17. ncbi Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance
    Frigga Roggel
    Klinische Forschergruppe der Frauenklinik, Technische Universitat Munchen, Ismaninger Strasse 22, 81675 Munich, Germany
    Recent Results Cancer Res 162:89-100. 2003
    ....